Oncogene-addicted non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the application of the concept “oncogene addiction”, which postulates that a cancer cell exhibits dependence on a single oncogenic pathway or protein for its sustained proliferation or survival, in the development of targeted therapies for non-small cell lung cancer (NSCLC).